Skip to content
CuraVeyra
Explore Clinical DemoLet's talk

Regulatory & Clinical Validation

Advancing Toward U.S. Clinical and Regulatory Readiness.

CuraVeyra is following a structured approach to software classification, clinical evaluation, medical device integration and applicable U.S. regulatory requirements.

Illustrative medical technology research environment

Regulatory roadmap

Seven stages. Honest status.

Technology developedIn integration / validationPlanned next step
  1. 1

    Stage 1 — Platform Development

    Technology developed

    Existing Telemedical technology foundation.

  2. 2

    Stage 2 — Device Integration and Technical Verification

    In integration / validation

    Reviewing compatible connected medical devices, data reliability, interoperability and security requirements.

  3. 3

    Stage 3 — Intended Use and Regulatory Classification

    In integration / validation

    Defining intended medical purposes and determining which software functions may be regulated medical device functions.

  4. 4

    Stage 4 — FDA Interaction Planning

    Planned next step

    Preparing an appropriate FDA engagement strategy, including evaluation of the Q-Submission / Pre-Submission process where relevant.

  5. 5

    Stage 5 — Clinical Evidence and Validation

    Planned next step

    Clinical study design, software verification, risk assessment and performance evaluation.

  6. 6

    Stage 6 — Applicable U.S. Premarket Pathway

    Planned next step

    Assessing 510(k), De Novo or other applicable pathways based on product classification and intended use.

  7. 7

    Stage 7 — U.S. Clinical Deployment

    Planned next step

    Deployment only when legally permitted and supported by the appropriate evidence, authorization and institutional agreements.

Public status statement

U.S. regulatory strategy and clinical validation preparation are underway. CuraVeyra has not been represented as FDA-cleared or FDA-approved.

Regulatory topics

What a responsible pathway involves.

Educational, forward-looking overview of topics we are working through — not a claim of completed compliance.

Intended useSoftware as a Medical Device (SaMD)FDA 510(k) / De Novo assessmentQuality management systemsSoftware lifecycle documentationRisk managementCybersecurityHuman factorsClinical validationAI model lifecycle governancePredetermined Change Control Plans where applicable

Clinical or regulatory expertise?

We welcome conversations with research hospitals and regulatory advisors.

Contact us